P50: A candidate ERP biomarker of prodromal Alzheimer's disease

Deborah L. Green, Lisa Payne, Robi Polikar, Paul J. Moberg, David A. Wolk, John Kounios

Research output: Contribution to journalArticlepeer-review

17 Scopus citations


Introduction Reductions of cerebrospinal fluid (CSF) amyloid-beta (Aβ42) and elevated phosphorylated-tau (p-Tau) reflect in vivo Alzheimer's disease (AD) pathology and show utility in predicting conversion from mild cognitive impairment (MCI) to dementia. We investigated the P50 event-related potential component as a noninvasive biomarker of AD pathology in non-demented elderly. Methods 36 MCI patients were stratified into amyloid positive (MCI-AD, n=17) and negative (MCI-Other, n=19) groups using CSF levels of Aβ42. All amyloid positive patients were also p-Tau positive. P50s were elicited with an auditory oddball paradigm. Results MCI-AD patients yielded larger P50s than MCI-Other. The best amyloid-status predictor model showed 94.7% sensitivity, 94.1% specificity and 94.4% total accuracy. Discussion P50 predicted amyloid status in MCI patients, thereby showing a relationship with AD pathology versus MCI from another etiology. The P50 may have clinical utility for inexpensive pre-screening and assessment of Alzheimer's pathology.

Original languageEnglish (US)
Pages (from-to)390-397
Number of pages8
JournalBrain Research
StatePublished - 2015
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • General Neuroscience
  • Molecular Biology
  • Clinical Neurology
  • Developmental Biology


Dive into the research topics of 'P50: A candidate ERP biomarker of prodromal Alzheimer's disease'. Together they form a unique fingerprint.

Cite this